04:51 PM EDT, 09/09/2025 (MT Newswires) -- Johnson & Johnson ( JNJ ) said the US Food and Drug Administration approved Inlexzo, formerly known as TAR-200, to treat certain types of bladder cancer.

The approval was supported by data from a Phase 2b clinical study, which showed 82% of patients with Bacillus Calmette-Guerin-unresponsive non-muscle invasive bladder cancer achieved a complete response and 51% remained cancer-free for at least a year, Johnson & Johnson ( JNJ ) said late Tuesday in a statement.